Miniproteins may have a big impact:new therapeutics for autoimmune diseases and beyond  

作　　者：Nariaki Asada Christian F.Krebs Ulf Panzer 

机构地区：[1]Department of Medicine,University Medical Center Hamburg-Eppendorf,Hamburg,Germany [2]Hamburg Center for Translational Immunology,University Medical Center Hamburg-Eppendorf,Hamburg,Germany [3]Hamburg Center for Kidney Health(HCKH),University Medical Center Hamburg-Eppendorf,Hamburg,Germany

出　　处：《Signal Transduction and Targeted Therapy》2024年第11期4785-4787,共3页信号转导与靶向治疗（英文）

基　　金：supported by grants from the Deutsche Forschungsgemeinschaft(DFG)to U.P.(SFB 1192 A1 and C3);C.F.K.(SFB 1192 A5 and C3,KR 3483/3-1).

摘　　要：In a landmark study recently published in Cell,Berger et al.demonstrated that computationally designed miniproteins could serve as novel,orally available treatment strategies by specifically targeting cytokine signaling pathways through the potent inhibition of ligand-receptor interactions in the body.1 This breakthrough study unveils the potential for miniprotein-based therapies to revolutionize molecular treatment strategies for autoimmune diseases and cancers.

关 键 词：AUTOIMMUNE DISEASES 

分 类 号：R593[医药卫生—内科学]